Acycloguanosine: antiviral activity in the rabbit cornea

M. G. FALCON AND B. R. JONES

From the Department of Clinical Ophthalmology, Institute of Ophthalmology, University of London

SUMMARY We describe experiments, using the multiple microinoculation technique, to produce superficial herpes simplex keratitis in the rabbit cornea, which showed a potent antiviral effect of acycloguanosine.

Although they are usually effective for the treatment of epithelial herpes simplex keratitis, idoxuridine (IDU), adenine arabinoside (ara-A), and trifluorothymidine (F3T) have limitations of solubilities and toxicity which render them inadequate for the management of deep herpetic disease. Acycloguanosine (Wellcome 248U) shows promise of overcoming these limitations. It is soluble in water (as the sodium salt), and has low toxicities from both topical ocular and systemic administration in several animal species (Schaeffer et al., 1978; Tucker et al., 1978) and man. It has potent antiviral activity against herpes simplex virus (HSV) types I and II, both in vitro and in vivo (Elion et al., 1977; Bauer et al., 1979).

As a preliminary to our first clinical trial of 248U, which has now been completed (Jones et al., 1979), and in order to compare data from our own laboratory with those of others (Bauer et al., 1979) we investigated the efficacy and tolerability of 248U in our rabbit corneal lesion inhibition system (Falcon and Jones, 1977a).

Methods

Details of the multiple microinoculation technique of Jones and Al-Hussaini, and of its modification to produce a corneal epithelial lesion inhibition assay, are published elsewhere (Jones and Al-Hussaini, 1963; Falcon and Jones, 1977a). In summary, 25 circular sites are inoculated on each eye of anaesthetised adult Dutch rabbits by means of a capillary tube of 1 mm diameter filled with pH 8 strain of HSV (of $1.5 \times 10^3$ plaque-forming units/ml). Treatment generally begins 2 hours after inoculation and is administered 5 times daily. 48 hours after inoculation each site is scored 0 to 4 according to the number of sites infected, and a corneal epithelial lesion inhibition assay (CEILA) is produced by comparing treated with control eyes in groups of 3 or 4 rabbits (which gives statistically valid results). The advantage of this lesion-inhibition system is that the lesions are small and discrete at the time of scoring, which provides rapid, accurate, and repeatable results from the minimum of animals, and the experiment can be terminated before the eyes have become uncomfortable.

Results

Experiments were performed to give a dose/response curve for 248U ointment. This was compared with ara-A ointment, and ara-A 5’ monophosphate (ara-AMP) ointment, which had been shown previously to give greater lesion inhibition than any other antiviral tested in this system (Falcon and Jones, 1977b). It was also compared with standard 0.5% IDU ointment and with 1% F3T drops (Fig. 1). We had shown previously that a single dose of...
ara-AMP given directly after inoculation had an almost catastrophic lesion-inhibiting effect, whereas IDU, ara-A, or F3T had little effect (Falcon and Jones, 1977b). 248U was employed in the same system and likewise had very little effect (Fig. 2).

In experiments to investigate the effect of systemic 248U, 50 mg/kg of 248U was given intravenously twice daily, the injections starting 2 hours after inoculation, and this experiment was continued for 72 hours. At 48 hours there was a small difference in scores between treated and control animals, and this had increased very considerably by 72 hours (Fig. 3).

Although this model, and particularly the scoring system, were derived primarily for lesion-inhibition experiments, we attempted to use them to assess therapy of established lesions: treatment began 48 hours after inoculation and was given 5 times daily. Scoring was carried out immediately before the beginning of the treatment and subsequently after 3 and 5 more days. We compared control, oculentum IDU 0.5%, oculetum ara-A 1%, oculetum ara-AMP 1%, guttae ara-AMP 1%, guttae F3T 1%, and guttae 248U 1%. It proved impossible to produce meaningful scores, since the lesions 48 hours from inoculation had already spread away from the inoculation sites. We therefore merely scored each eye as 'healed' or 'unhealed' (Table 1).

**Discussion**

Fig. 1 shows that the dose/response curves for 248U and ara-A are very similar, and it shows that the efficacy of 1% and 2% 248U ointment, as measured by lesion inhibition, is comparable to that of 1% F3T drops. The dose/response curve for ara-AMP indicates a substantially superior antiviral effect, but this has been shown to be due to the unique and profound lesion-inhibiting effect of ara-AMP when given shortly after inoculation (Falcon and Jones, 1977b) (Fig. 2). ara-AMP has proved too toxic for practicable clinical application to the eye.

These lesion-inhibiting experiments thus indicate a useful potential for topical 248U, which is supported by our experiments in the treatment of established lesions (Table 1), though these have emphasised the limitations of this method.

Our experiments with intravenous 248U therapy demonstrate an encouraging antiviral effect in the cornea, although, as might be expected, this is delayed in comparison with the effect of topical treatment. Experiments are now in progress to establish a model of deep herpetic keratitis and to investigate the role of subconjunctival and systemic 248U therapy for it. These routes may prove to be the most effective means of achieving a good intraocular level of the drug, since very low aqueous levels of 248U were obtained after its application to the cornea, whether or not the epithelium was breached (Bauer, personal communication). The water solubility and low toxicity of 248U should provide no barriers to such therapy and indeed offer possibilities for safe and effective therapy of herpes virus infections throughout the body.

---

**Table 1** Number of eyes healed (out of 3 in each group), 3 and 5 days after start of antiviral treatment, which was given 5 times daily, starting 48 hours after inoculation

<table>
<thead>
<tr>
<th>Antiviral</th>
<th>At 3 days</th>
<th>At 5 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Oculentum IDU 0.5%</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Oculentum Ara A 1%</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Oculentum Ara AMP 1%</td>
<td>0*</td>
<td></td>
</tr>
<tr>
<td>Guttae F3T 1%</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Guttae 248U 1%</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

* Severe toxic epitheliopathy at this stage
We are indebted to the following: Wellcome Research Laboratories Ltd., Beckenham, for provision of 248U; Parke-Davis & Co., Ann Arbor, Michigan, USA, for provision of Ara A and Ara AMP; Mr R. Watkins, chief pharmacist, and staff, who prepared the antivirals; and Dr P. Collins, Wellcome Laboratories, for provision of HSV pools.

References


